Stiris Research Inc. exceeds recruitment targets in Phase II Meniere’s disease study

London, ON — October 31, 2016 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces that it has exceeded the expected recruitment targets on a US biotechnology company’s Phase II Meniere’s disease study.

“We are excited to see the improvements this treatment will provide, and we are now able to do this sooner, because of the rapid enrollment that has occurred in Canada.” Clinical Lead (Sponsor).

“Our five Canadian sites have all worked really hard to achieve their enrollment targets, in fact have exceeded the sponsors requirement on enrollment by 340% and have allowed the sponsor to close enrollment early. This speaks volumes about Stiris’ collaborative teamwork, site relationships, site engagement and a novel study that shows tremendous help for these patients suffering with Meniere’s disease,” said Amanda Carrera, Vice President.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.